Uncovering the Anticancer Potential of Polydatin: A Mechanistic Insight
Muhammad Ajmal Shah, Ayesha Hamid, Hafiza Ishmal Faheem, Azhar Rasul, Tourki A. S. Baokbah, Muhammad Haris, Rimsha Yousaf, Uzma Saleem, Shabnoor Iqbal, Maria Silvana Alves, Zahid Khan, Ghulam Hussain, Ifat Alsharfi, Haroon Khan, Philippe Jeandet
Abstract
extracts are used for the treatment of infections, inflammation, and cardiovascular disorders. Polydatin possesses a broad range of biological activities including antioxidant, anti-inflammatory, anticancer, and hepatoprotective, neuroprotective, and immunostimulatory effects. Currently, a major proportion of the population is victimized with cervical lung cancer, ovarian cancer and breast cancer. PD has been recognized as a potent anticancer agent. PD could effectively inhibit the migration and proliferation of ovarian cancer cells, as well as the expression of the PI3K protein. The malignancy of lung cancer cells was reduced after PD treatments via targeting caspase 3, arresting cancer cells at the S phase and inhibiting NLRP3 inflammasome by downregulation of the NF-κB pathway. This ceases cell cycle, inhibits VEGF, and counteracts ROS in breast cancer. It also prevents cervical cancer by regulating epithelial-to-mesenchymal transition (EMT), apoptosis, and the C-Myc gene. The objective of this review is thus to unveil the polydatin anticancer potential for the treatment of various tumors, as well as to examine the mechanisms of action of this compound.